HUDDINGE, Sweden, Dec. 15, 2022 /PRNewswire/ — XNK Therapeutics AB (“XNK”) today announced that the first patient has donated cells in the recently initiated preclinical evaluation of the autologous NK cell product XNK03 in locally advanced or metastatic urothelial cancer. The study is performed in collaboration with Anders Ullén’s research group at the Karolinska University Hospital, Stockholm, Sweden.
This is the company’s first solid tumor indication and complements the ongoing Phase II clinical study in multiple myeloma (MM) and the preclinical proof-of-concept study in acute myeloid leukemia (AML) using patient samples from The University of Texas MD Anderson Cancer Center. Between 10-15 patients with advanced urothelial cancer will be enrolled in the study and will donate cells before and after chemotherapy treatment.
“The possibility to confirm that our proprietary technology can successfully expand and activate NK cells from the exact patient population we intend to treat in the future is an important step towards a clinical study,” said Johan Liwing, CEO of XNK Therapeutics. “We are enthusiastic about this joint effort with the Karolinska University Hospital to seek out more effective treatments in a patient population with high and unmet medical need.”
Urothelial cancer is the most common form of bladder cancer. More than 80,000 new cases of bladder cancer are expected in the US in 2022 alone, according to the American Cancer Society.
Source: BioSpace
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.